Market Research Logo

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides an overview of the Hematopoietic Stem Cell Transplantation (Immunology) pipeline landscape.

Hematopoietic stem cell transplantation (HSCT) involves the intravenous (IV) infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. Predisposing risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Treatment includes immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 3 and 1 respectively for Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hematopoietic Stem Cell Transplantation Overview
Therapeutics Development
Pipeline Products for Hematopoietic Stem Cell Transplantation - Overview
Hematopoietic Stem Cell Transplantation - Therapeutics under Development by Companies
Hematopoietic Stem Cell Transplantation - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Hematopoietic Stem Cell Transplantation - Products under Development by Companies
Hematopoietic Stem Cell Transplantation - Companies Involved in Therapeutics Development
Actinium Pharmaceuticals, Inc.
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Cell2B S.A.
Celldex Therapeutics, Inc.
Kiadis Pharma N.V.
Novartis AG
P2D Bioscience
Taiga Biotechnologies, Inc.
Targazyme, Inc.
Hematopoietic Stem Cell Transplantation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ATIR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPX-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Casin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CordSafe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSC-835 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iomab-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05285401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TZ-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hematopoietic Stem Cell Transplantation - Dormant Projects
Hematopoietic Stem Cell Transplantation - Discontinued Products
Hematopoietic Stem Cell Transplantation - Product Development Milestones
Featured News & Press Releases
Jun 30, 2016: Kiadis Pharma Orphan Drug Designation for ATIR101 further expanded to include treatment in a hematopoietic stem cell transplantation
May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting
Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B
Apr 06, 2016: Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101
Mar 30, 2016: Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101
Mar 08, 2016: Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B
Feb 20, 2016: Celldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
Feb 02, 2016: Actinium Pharmaceuticals Announces Participation at Upcoming Annual Meeting of Pre-Eminent Blood and Marrow Transplant Organization
Nov 30, 2015: Actinium to Present on Iomab-B at 8th Annual LD Micro Main Event Conference on December 2, 2015
Apr 23, 2015: Targazyme Announces FDA Concurrence On Targazyme’s Special Protocol Assessment For A Planned Phase 3 Registration Trial For The Treatment Of Patients With Hematologic Malignancie
Mar 17, 2015: Targazyme and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
Feb 10, 2015: Targazyme Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
Sep 25, 2014: Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Athersys, Inc., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Cell2B S.A. , H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Celldex Therapeutics, Inc., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Kiadis Pharma N.V., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Novartis AG, H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by P2D Bioscience, H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Taiga Biotechnologies, Inc., H2 2016
Hematopoietic Stem Cell Transplantation - Pipeline by Targazyme, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hematopoietic Stem Cell Transplantation - Dormant Projects, H2 2016
Hematopoietic Stem Cell Transplantation - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report